{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'hematological practice. Study treatment should be discontinued if blood counts do not recover', 'to CTC grade 1 or better within 4 weeks of dose interruption.', 'Development of a confirmed myelodysplastic syndrome or other clonal blood disorder should', 'be reported as an SAE and full reports must be provided by the investigator to AstraZeneca', \"Patient Safety. Olaparib treatment should be discontinued if patient's diagnosis of MDS\", 'and/or AML is confirmed.', '8.2.8', 'Management of non-hematological toxicity', 'Repeat dose interruptions are allowed as required, for a maximum of 4 weeks on each', 'occasion. If the interruption is any longer than this the study monitor must be informed.', 'Where toxicity reoccurs following re-challenge with study treatment, and where further dose', 'interruptions are considered inadequate for management of toxicity, then the patient should be', 'considered for dose reduction or must permanently discontinue study treatment.', 'Study treatment can be dose reduced to 250 mg bid as a first step and to 200 mg bid as a', 'second step. Treatment must be interrupted if any NCI-CTCAE grade 3 or 4 adverse event', 'occurs which the investigator considers to be related to administration of study treatment.', '8.2.8.1 Management of new or worsening pulmonary symptoms', 'If new or worsening pulmonary symptoms (e.g., dyspnea) or radiological abnormalities occur', 'in the absence of a clear diagnosis, an interruption in study treatment dosing is recommended', 'and further diagnostic workup (including a high resolution CT scan) should be performed to', 'exclude pneumonitis.', 'Following investigation, if no evidence of abnormality is observed on CT imaging and', 'symptoms resolve, then study treatment can be restarted, if deemed appropriate by the', 'investigator. If significant pulmonary abnormalities are identified, these need to be discussed', 'with the Study Physician.', '8.2.8.2', 'Management of nausea and vomiting', 'Events of nausea and vomiting are known to be associated with olaparib treatment. In study', 'D0810C00019 nausea was reported in 71% of the olaparib treated patients and 36% in the', 'placebo treated patients and vomiting was reported in 34% of the olaparib treated patients and', '14% in the placebo treated patients. These events are generally mild to moderate (CTCAE', 'grade 1 or 2) severity, intermittent and manageable on continued treatment. The first onset', 'generally occurs in the first month of treatment for nausea and within the first 6 months of', 'treatment for vomiting. For nausea, the incidence generally plateaus at around 9 months, and', 'for vomiting at around 6 to 7 months.', 'No routine prophylactic anti-emetic treatment is required at the start of study treatment,', 'however, patients should receive appropriate anti-emetic treatment at the first onset of nausea', 'or vomiting and as required thereafter, in accordance with local treatment practice guidelines.', 'Alternatively, olaparib tablets can be taken with a light meal/snack (eg, 2 pieces of toast or a', 'couple of biscuits).', '65(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'As per international guidance on anti-emetic use in cancer patients (ESMO, NCCN), generally', 'a single agent antiemetic should be considered (eg, dopamine receptor antagonist,', 'antihistamines or dexamethasone).', '8.2.8.3', 'Interruptions for intercurrent non-toxicity related events', 'Study treatment dose interruption for conditions other than toxicity resolution should be kept', 'as short as possible. If a patient cannot restart study treatment within 4 weeks for resolution of', 'intercurrent conditions not related to disease progression or toxicity, the case should be', 'discussed with the primary investigator (Dr. Michael Schweizer).', 'All dose reductions and interruptions (including any missed doses), and the reasons for the', 'reductions/interruptions are to be recorded in the eCRF.', 'Study treatment should be stopped at least 3 days prior to planned surgery. After surgery study', 'treatment can be restarted when the wound has healed. No stoppage of study treatment is', 'required for any needle biopsy procedure.', 'Study treatment should be discontinued for a minimum of 3 days before a patient undergoes', 'radiation treatment. Study treatment should be restarted within 4 weeks as long as any bone', 'marrow toxicity has recovered.', 'Because the AEs related to olaparib may include asthenia, fatigue and dizziness, patients', 'should be advised to use caution while driving or using machinery if these symptoms occur.', 'Table 5', 'Dose reductions for olaparib treatment.', 'NOTE: Dose of testosterone will remained fixed throughout the study. Dose', 'reductions in testosterone could result in physiologic serum T levels, which in', 'contrast to supraphysiologic levels, may promote tumor growth.', 'Initial Dose', 'Following re-challenge post', 'Dose reduction 2', 'interruption: Dose reduction 1', '300mg twice daily', '250mg twice daily', '200mg twice daily', '8.3', 'Concomitant and post-study treatment(s)', 'The use of any natural/herbal products or other traditional remedies should be discouraged,', 'but use of these products, as well as any medication or vaccine including over-the-counter or', 'prescription medicines, vitamins, and/or herbal supplements that the patient is receiving at the', 'time of enrolment or receives during the study must be recorded along with:', 'Reason for use', 'Dates of administration including start and end dates', 'Dosage information including dose and frequency', '66(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}